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Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled
in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using in-
dividual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs
were identified through literature search until December 2018. Individual participant survival was recon-
structed with an algorithm from published Kaplan–Meier curves. Results: Ten RCTs were included. Median
OS was 10.0 months (95% CI: 9.6–10.5), and median TTP was 4.1 months (95% CI: 3.8–4.3). Multivariable
analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors
of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results
can be used in the decision making for the early shift to second-line strategy.
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Hepatocellular carcinoma (HCC) is a malignancy of global importance that exhibits considerable clinical and
biological heterogeneity [1,2] and, in most cases, a dismal prognosis [3]. Despite the extensive application of
surveillance programs for the early detection, more than half of HCC patients are diagnosed at a stage for which
there are no potentially curative treatment options.
The oral multikinase inhibitor sorafenib is recommended as the standard first-line systemic therapy for com-
pensated patients with advanced HCC and for those with an intermediate HCC deemed unfit for, or who fails
to respond to loco-regional therapies [3,4]. Two Phase III randomized controlled trials (RCTs) showed a significant
advantage in terms of survival against placebo [4,5]. Since its successful approval, several systemic and intra-arterial
therapies have been tested against sorafenib in the first-line (either in noninferiority or in superiority trials) [6] or
in the second-line settings [7]. Among these, as first-line therapies only lenvatinib RCT [8] met its (noninferiority)
end point, whereas regorafenib [9], cabozantinib [10] and ramucirumab [11] showed survival benefit against placebo
for patients in the second line setting.
Efficacy and cost–effectiveness of sorafenib for HCC have been widely assessed in clinical practice [12–14] showing
that treatment with sorafenib is characterized by high rates of anticipated discontinuation caused by tumor
progression, liver decompensation and adverse events (AEs) both in RCTs [4,5] and in field practice studies [12,15,16].
Molecular predictors of response are still lacking and the determination of the optimal point at which to move
from first- to second-line therapy is a major goal in the management of these patients. Important questions still
remain: ‘which is the best time to switch from sorafenib to second-line systemic therapy?’ as well as ‘what are the
most determinants of tumor progression?’. An accurate estimation of death and risks of progression among these
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patients is essential for assessing therapeutic effect of any new treatment strategy, for calculating sample sizes and
interpreting results of second line clinical trials, as well as for cost–effectiveness analysis purposes.
To develop a more comprehensive picture of sorafenib benefit and to increase statistical power for future
study designs, we present there a meta-analysis of available high-level evidences by using reconstructed ‘individual
participant (IP) survival data’ of Phase III RCTs. Themain aimwas to provide a robust benchmark of survival figures
achievable with sorafenib treatment and eventually identify possible predictors of death and tumor progression.
Methods
Structure of the study
The term ‘individual participant data’ (IPD) relates to the data recorded for each participant in a study and, as with
any meta-analysis, an IPD meta-analysis aims to summarize the evidence on a particular clinical question from
multiple related studies [17]. Unfortunately, despite calls for increased access to IPD from clinical trials, progress
toward this is frustratingly slow [18]. We obtained IP survival data through the reconstruction of survival data from
the published Kaplan–Meier curves [19]. Subsequently, we applied a one-step meta-analytic approach to preserve
the clustering of patients within studies and to implement the estimate of the effect of potential clinical features on
the outcome of interest [17].
The present meta-analysis was therefore organized as follows: identify available Phase III RCTs evaluating
sorafenib as first-line therapy for intermediate/advancedHCC; reconstruct IP survival data from published Kaplan–
Meier curves using an appropriate algorithm; apply a flexible parametric survival model which allows for study
clustering.
Identification of eligible studies
This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement [20].
A systematic search of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CEN-
TRAL) databases was performed for articles published up to 31 December 2018 with no lower date limit, including
the following key words: ‘HCC’, ‘sorafenib’, ‘RCTs’. Details of the literature search strategy and quality assessment
can be found in the Supplementary File 1. Studies were included in the analysis if: they were Phase III RCTs
comparing sorafenib as mono-therapy with placebo or any other therapy; they included advanced HCC patients
with or without extra-hepatic disease, or intermediate HCCs deemed unfit or failing locoregional therapies; overall
survival (OS) and/or time to radiological progression (TTP) were assessed as outcome measures of the effect of
the treatment since randomization; and they had been published as full-length articles. Reasons for exclusion from
the present study are detailed in the Figure 1. We evaluated the methodological quality of the included studies
using five criteria (Supplementary Table 1), as established by Jadad et al. [21], Ban˜ares et al. [22] and by the Panel of
Experts in HCC-design clinical trials [23]. We assessed the quality of trials according to each separate component,
with a maximum possible score of ten points. Studies published only in abstract form were excluded because the
methodological quality can not be assessed.
Reconstruction of IP survival data
To reconstruct IP survival, the algorithm provided by Guyot et al. was applied [19]. This algorithm returns a list
of ‘participants’ with a predicted survival time together with the predicted event of interest (i.e., alive or death;
progression or no progression) and showed an excellent accuracy for survival probabilities and medians. Briefly, the
algorithm uses the digitalized data on survival probabilities, time and total number of patients, and events to find
numerical solutions to the inverted Kaplan–Meier equations. Data were digitalized using Engauge Digitize (version
10.4), a free open source tool for extracting numeric data from images or graphs. The algorithm was implemented
in R (version 3.4.3; R Core Team (2013). R: a language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria). Each reconstructed survival curve, either OS or TTP, was visually
inspected for accuracy with respect to the original published Kaplan–Meier by overlapping the obtained curve with
the published one and by comparing median OS/TTP published with those reconstructed.
To provide further calibration of reconstructed OS, the obtained median values were compared with the pooled
median calculated with the method provided by Combescure et al. [24]. This approach returns a distribution-free
summary survival curve by expanding the product-limit estimator of survival for aggregated survival data. This
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Figure 1. Study flowchart.
approach was implemented in R and used package ‘metasurv’, which contains the data extracted from already
published survival rates of untreated patients in randomized clinical trials of HCC [1].
Application of survival model to IPD
Once IP survival data were obtained, common Kaplan–Meier curves were plotted. Subsequently, the average value
of included moderators was added to the reconstructed data. Since no specific IPD on moderators was available, we
were forced to model a ‘frailty’ survival model in a one-step approach. A flexible parametric approach was chosen
because it more accurately models survival avoiding the proportional hazard assumption, through the application
of splines (knots).
For mortality, knots were placed at 3, 6, 9 and 12 months, and for progression knots were placed at 1, 3
and 6 months since randomization. Frailty accounted for study clustering returning a measure for unobserved
heterogeneity that occurs because some unexplained observations are more failure prone (more ‘frail’) than other
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Table 1. Main characteristics of patients receiving sorafenib in the Phase III trials included in the meta-analysis.
Study (year) Versus n Age, years (SD) HCV+ (%) CTP-A (%) ECOG-0 (%) MaVI+ (%) EHD+ (%) BCLC-C (%) Quality Ref.
Llovet et al. (2008) Placebo 299 64.9 (11.2) 29.1 95.0 53.8 36.1 53.2 81.6 10 [4]
Cheng et al. (2009) Placebo 150 52.8 (18.2)† 10.7 97.3 25.3 36.0 68.7 95.3 10 [5]
Johnson et al. (2013) Brivanib 578 58.5 (18.5)† 20.6 91.9 60.9 27.3 50.3 77.7 9 [24]
Cheng et al. (2013) Sunitinib 544 55.0 (19.0)† 21.9 99.8 53.5 30.5 64.9 83.5 8 [25]
Cainap et al. (2015) Linifanib 521 57.5 (18.5)† 24.8 94.6 66.0 40.5 56.8 80.2 4 [26]
Zhu et al. (2015) +Erlotinib 358 NA 23.5 100 60.3 42.7 61.2 86.6 10 [27]
Kudo et al. (2018) Lenvatinib 476 58.5 (19.0)† 26.0 99.0 63.0 19.0 62.0 81.0 8 [8]
Villgrain et al. (2018) SIRT 222 65.3 (11.2)† 22.1 84.2 62.6 57.7 0.0 67.1 6 [28]
Chow et al. (2018) SIRT 178 57.7 (10.6) 13.5 89.9 79.2 30.3 0.0 44.9 8 [29]
Kudo et al. (2018) +HAIC 103 68.1 (9.1) 45.0 90.0 88.0 62.0 25.0 74.0 8 [30]
†
Calculated from median and range using the formula proposed by Wan [32].
The manuscript from Zhu et al. did not report ranges to estimate the mean and the SD of patient age.
CTP: Child-Turcotte-Pugh; ECOG: Eastern Cooperative Oncology Group; EHD: Extra-hepatic disease; HAIC: Hepatic arterial infusion chemotherapy; MaVI: Macroscopic vascular invasion;
NA: Not available/not assessable; SD: Standard deviation; SIRT: Selective internal radiation therapy.
Table 2. Pooled results of clinical and tumoral features considered as potential moderators for overall survival and
time-to-radiological progression in the flexible parametric survival model.
Parameter Number of at-risk patients Estimate (95% CI) I2 Ref.
Clinical features
Hepatitis C positive (%) 3429 22.9 (19.3–27.0) 85.2% [4,5,8,23–29]
Child–Pugh A (%) 3429 95.4 (92.3–97.2) 88.3% [4,5,8,23–29]
ECOG–0 (%) 3429 61.8 (54.8–68.3) 93.6% [4,5,8,23–29]
Tumor features
Macrovascular invasion (%) 3429 37.3 (30.2–44.9) 94.6% [4,5,8,23–29]
Extra-hepatic disease (%) 3429 52.4 (44.9–59.8) 92.3% [4,5,8,23–29]
BCLC–C (%) 3429 78.9 (72.1–84.4) 94.4% [4,5,8,23–29]
Meta-analysis results are reported as pooled estimates and 95% confidence intervals; continuous variables are reported as weighted means and categorical variables as weighted propor-
tions.
I2 values of 25% were interpreted as low heterogeneity, between 25 and 50% as medium, between 50 and 75% as substantial and above 75% as considerable.
BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group.
observations in the dataset. Frailty was here group-specific, generated by each of the study included. The parametric
frailty model was implemented in STATA (StataCorp. 2015. Stata Statistical Software: Release 14, StataCorp LP,
TX, USA).
Results
Literature search results
A total of 224 articles were identified using our search criteria for screening (Figure 1). Following the adopted
exclusion criteria, 10 Phase III RCTs were retained (Table 1) [4,5,8,25–31]. Of the 10 RCTs, two compared sorafenib
with placebo [4,5], five compared sorafenib with other systemic agents [8,25–28], two compared sorafenib with selective
internal radiation therapy [29,30], and one with sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial
infusion chemotherapy [31]. The risk of bias according to the Jadad tool was graded as ‘low’ for most of domains
(Supplementary Table 2).
Characteristics of included patients
The pooled study cohort consisted of 3429 individual HCC patients fulfilling eligibility criteria and receiving
sorafenib. Meta-analysis of clinical and tumor features considered as potential moderators in the successive survival
analysis are reported in Table 2. As can be noted, pooled estimates showed a considerable degree of heterogeneity for
all potential moderators (I2 > 75%) supporting the different role of each feature in producing a different outcome
in terms of OS and TTP.
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Table 3. Comparison between published median values of overall survival and time-to-progression and those based on
reconstructed individual participant data.
Study (year) Median OS (months; 95% CI) Median TTP (months; 95% CI) Ref.
Published Reconstructed Published Reconstructed
Llovet et al. (2008) 10.7 (9.4–13.3) 10.7 (9.1–12.1) 5.5 (4.1–6.9) 5.5 (4.2–6.9) [4]
Cheng et al. (2009) 6.5 (5.6–7.6) 6.5 (5.2–7.7) 2.8 (2.6–3.6) 2.8 (2.6–3.0) [5]
Johnson et al. (2013) 9.9 (8.5–11.5) 9.9 (8.8–10.9) 4.1 (3.1–4.2) 4.1 (3.6–4.5) [24]
Cheng et al. (2013) 10.2 (8.9–11.4) 10.3 (9.1–11.4) 3.8 (2.9–4.2) 3.9 (3.5–4.3) [25]
Cainap et al. (2015) 9.8 (8.3–11.0) 9.8 (8.8–10.9) 4.0 (2.8–4.2) 4.1 (3.5–4.7) [26]
Zhu et al. (2015) 8.5 (7.4–10.6) 8.6 (7.0–10.2) 4.0 (2.9–4.5) 4.0 (3.3–4.7) [27]
Kudo et al. (2018) 12.3 (10.4–13.9) 12.3 (10.6–14.0) 3.7 (3.6–5.4) Na [8]
Villgrain et al. (2018) 9.9 (8.7–11.4) 9.9 (8.7–11.2) Na Na [28]
Chow et al. (2018) 10.0 (8.6–13.8) 10.1 (7.5–14.9) 5.4 (4.1–5.7) 5.4 (4.7–6.1) [29]
Kudo et al. (2018) 11.5 (8.2–14.8) 11.4 (9.6–10.6) 3.5 (3.9–6.7) 3.5 (2.8–4.6) [30]
The first study from Kudo et al. [8]. reported the median TTP in the text but not the corresponding curve, thus, reconstruction was unfeasible. The study from Villgrain et al. [28] did not
report median TTP; additionally, for estimation of TTP a competing-risk analysis was adopted, thus, making impossible to reconstruct, and validate, any TTP curve.
OS: Overall survival.
The size of the sorafenib arms in each study ranged from 103 [31] to 578 patients [25]. The mean patient age
ranges from 52.8 [5] to 68.1 years [31]. The proportion of patients with HCV-related HCC ranged from 10.7 [5] to
44.7% [31]. The percentage of Child–Pugh A patients ranged from 84.2 [29] to 100% [31], while the frequency of an
ECOG-PS = 0 went from 25.3 [5] to 88.3% [31]. The proportion of patients with macrovascular invasion (MaVI),
as well as with extra-hepatic disease (EHD) differed greatly among the trials, ranging from 18.9 [8] to 62.2% [31],
and from 0 [29,31] (in the two RCTs comparing Sorafenib vs selective internal radiation therapy) with 68.7% [5],
respectively.
Methodological quality scores varied from 4 [27] to 10 [4,5,28] on a scale of 2 to 10 (Supplementary Table 2).
All included trials reported an adequate efficacy of randomization, while an adequate follow-up was not reported
in only two studies [25,27]. Blinding was adequate in four RCTs [4,5,25,28]. A high-quality score (≥6 points) was
observed in nine trials (90%) [4,5,8,25,26,28–31].
The comparison between published OS and TTP median values and those based on reconstructed IP survival
data are reported in Table 3. As can be noted, reconstructed medians were really similar, if not identical, to those
reported in each of the study included. Confidence intervals were also quite similar each other providing robustness
to reconstructed IP survival data. The complete list of the 3429 patients with reconstructed survival data is available
in Supplementary File 2 (Reconstructed IP survival data).
Overall survival
The entire OS curve using IP survival data of 3429 patients is reported in Figure 2, Panel A. The median OS
calculated by this way was 10.0 months (95% CI: 9.6–10.5). This figure was very similar to the median calculated
by pooling each OS curve (Combescure approach) of 9.9 months [24], albeit with slightly wider confidence intervals
in the latter (95% CI: 8.9–11.0). In both cases, median survivals were significantly higher (Log-rank p < 0.001)
than the pooled median of 5.7 months (95% CI: 4.5–6.7) already calculated for untreated 1813 HCC patients
enrolled in RCTs of palliative treatments (Figure 3) [1].
Results from frailty survival models are reported in Table 4. On multivariable analysis, it was observed that
positivity for HCV significantly defined a group of patients with better OS (p = 0.001), and that the presence of
MaVI and EHD determined significant worse prognosis (p = 0.001 in both cases). The frailty model returned a θ
with p = 0.119, indicating that these features accounted for the majority of overdispersion due to variables not
accounted for within-study level.
Time to radiological progression
Reconstruction of IP data for TTP was feasible for 2731 patients, since Kudo et al. [8]. and Villgrain et al. [29]. did
not provide necessary data or curves in their manuscripts. The reconstructed TTP curve is reported in Figure 2,
Panel B. The median TTP calculated through IPD was of 4.1 months (95% CI: 3.8–4.3), again, a figure very
similar to the median obtained by pooling each TTP curve of 4.2 months (95% CI: 3.7–4.7).
future science group 10.2217/fon-2019-0287
Systematic Review Cabibbo, Cucchetti, Camma` et al.
0.00
0.25
Months since randomization
O
ve
ra
ll 
su
rv
iv
al
3 60
At risk pts. 3429 2234 1221 595 257 105 52 6 2
9 12 15 18 48
1.00
0.50
0.75
21 24 27 30 33 36 39 42 45
0.00
0.25
P
ro
b
ab
ili
ty
 o
f 
ra
d
io
lo
g
ic
al
 p
ro
g
re
ss
io
n
At risk pts. 2731 1131 570 292 170 97 67 39
1.00
0.50
0.75
Months since randomization
3 60 219 12 15 18
Figure 2. Kaplan–Meier curves reporting outcomes of patients with intermediate/advanced hepatocellular
carcinoma treated with sorafenib deriving from individual participant survival data: overall survival of 3429 patients
(A) and time to radiological progression of 2731 patients (B).
HCC: Hepatocellular carcinoma; OS: Overall survival.
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Figure 3. Comparison of overall survival estimates between 3429 patients treated with sorafenib and 1813
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line refers to patients treated with Sorafenib. The black dashed line refers to untreated HCC patients. The blue dotted
lines refer to confidence intervals of the two curves.
OS: Overall survival; HCC: Hepatocellular carcinoma.
Table 4. Results from frailty flexible parametric survival model incorporating splines.
Hazard ratio (95% CI) p-value
Mortality
HCV+ (%) 0.095 (0.038–0.234) 0.001
CTP A (%) 0.257 (0.328–2.015) 0.196
ECOG–0 (%) 1.308 (0.664–2.577) 0.438
MaVI+ (%) 4.590 (2.593–8.125) 0.001
EHD+ (%) 1.667 (1.262–2.202) 0.001
 (frailty variance) 0.002 (0.001–0.023) 0.119
Progression
HCV+ (%) 0.223 (0.049–1.015) 0.052
CTP A (%) 0.198 (0.006–6.455) 0.363
ECOG–0 (%) 0.854 (0.267–2.726) 0.790
MaVI+ (%) 4.772 (1.162–19.59) 0.030
EHD+ (%) 1.553 (1.044–2.310) 0.029
 (frailty variance) 0.008 (0.001–0.467) 0.041
Note: Bold entries refer to statistically significant associations.
Only variables available for all the studies included were analyzed. BCLC-C was not entered to avoid collinearity with its components (CTP, ECOG, MaVI and EHD)
For mortality, knots were placed at 3, 6, 9 and 12 months. For progression knots were placed at 1, 3 and 6 months. Splines were always statistically significant (p  0.05).
 represents the estimated variance of frailty at the study level. The corresponding p-values (Prob = chibar2) verify whether a significant variance component is still present after inclusion
of covariates. In other words, the coefficient  is a multiplicative random factor accounting for overdispersion of model fit due to lack of variable measurements that can vary within each
of the study included (so-called ‘shared frailty’).
CTP: Child-Turcotte-Pugh; ECOG: Eastern Cooperative Oncology Group; EHD: Extra-hepatic disease; MaVI: Macrovascular invasion.
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Results from frailty survival models are reported in Table 4. On the multivariable analysis, presence of MaVI and
EHD were the only variables significantly associated with rapid progression (p = 0.001 in both cases). The frailty
model returned a significant θ value (p = 0.041) indicating that a significant heterogeneity was still present due to
within-study variance.
Discussion
According to EASL HCC guidelines [3], sorafenib is recommended as the standard first-line systemic therapy for
compensated patients with advanced HCC and for those with an intermediate HCC deemed unfit for, or who
fail to respond to, locoregional therapies. In this study, we performed a meta-analysis of aggregate survival data of
single sorafenib arms from ten Phase III RCTs published when comparing placebo versus sorafenib and different
first-line therapies versus sorafenib as the standard of care for intermediate/advanced HCC. Our data revealed an
IP survival of 10.0 months and an IP median time to radiological progression of 4.1 months for sorafenib. To the
very best of our knowledge, the present one is the largest (>3000 individuals) and updated attempt to produce
such an IPD analyses in this clinical scenario.
The actuarial curve of OS obtained in this meta-analysis (Figure 2) can be considered a useful reference for
determining the sample size of future first-line systemic RCTs comparing new agents versus sorafenib, and for
obtaining indirect comparisons among different trials estimating drug efficacy. Similarly, our actuarial curve of
TTP represents the strongest estimate available to date regarding the risk of radiological progression, providing
another useful benchmark for suggesting the more appropriate time for stopping sorafenib and starting second-line
agents. As already stated, we provide as supporting excel file (Supplementary File 2) the complete list of the 3429
patients with reconstructed survival data. The free access to these data returns the possibility for its use in further
specific analyses.
As expected, different studies included different proportions of potential determinants for progression and
survival. The considerable heterogeneity observed among potential moderators (Table 2) inevitably translates into
the different survival figures reported in each RCTs, with median OS and TTP rates ranging from 6.5 to 12.3
months and from 2.8 to 5.5months, respectively (Table 3). Despite the final number of included patients in the IPD
analysis was large enough to suggest some strength, the confidence intervals of median OS and median TTP were
not particularly narrowed after the IPD analysis in respect to that of each single RCTs. However, within the present
analytical framework, this heterogeneity returns the unique possibility to apply a one-stage IPDmeta-analysis using
potential moderators, at their average values, as determinants of outcome.
With the preservation of study clustering, it was observed at multivariate analysis for OS, that absence of
MaVI and EHD, and presence of HCV etiology were the only significant predictors of longer survival. The
two tumor individual parameters, both included in the BCLC classification (which was excluded for evident
co-linearity), largely explain why this staging system provides accurate information on prognosis in the setting of
intermediate/advanced HCC and confirm that tumor burden at baseline has a relevant impact on survival in HCC
patients. Moreover, this finding is consistent with the results of SOFIA [12] and ITA.LI.CA. [33] cohorts, which
showed, in-field practice setting, a relevant role of baseline tumor burden during sorafenib treatment.We also found
that HCV etiology is a robust predictor of survival in HCC patients receiving sorafenib. Considering that: this
finding is consistent with results of two recent studies suggesting that the magnitude of survival benefit is greater
in HCV patients [34,35]; HCV etiology was a favorable prognostic factor for survival in untreated advanced HCC
patients [1]; and finally that, given the positive impact on decompensation and survival due to HCV eradication
by direct antiviral agents also in HCC patients [36–39], we can suggest to early shift to second-line therapies in
non-HCV-related HCC patients.
According to tumor-related variables, we found, as expected, that MaVI and EHD were independent predictors
of radiologic progression of HCC during therapy. These findings may help to: stratify patients according to these
HCC pretreatment features in future clinical studies and suggest an early shift to second-line therapies, for those
patients with these unfavorable tumor features who do not have clear evidence for response to sorafenib therapy.
According to liver-related variables, field-practice studies showed that sorafenib is frequently administered also
in patients with Child–Pugh class B and that OS of patients treated with sorafenib is longer in patients with Child–
Pugh class A in comparison with those in class B [12,40]. We did not observe a significant impact of Child–Pugh class
on OS, but it should be considered that in our meta-analysis the pooled estimated prevalence of Child–Pugh class
A was 95%. RCTs often excluded patients with more advanced liver disease, in those the progression of cirrhosis
toward liver decompensation represents a competitive risk for death.
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The methodology of the current study could be affected by the potential limitation of the generalizability of
its results to new populations and settings, as typically occurs in all meta-analyses. The included studies were
performed in highly specialized centres, both in Eastern and in Western areas. Although the overall sample size of
patients analyzed exceeded 3000, drawing firm conclusions may be premature. Heterogeneity in baseline severity of
illness (with or without extra-hepatic spread and/or MaVI), etiology (HBV, HCV, alcohol), and number and type
of prior therapy, may limit the accuracy of our results. We included patient- and study-level covariates to attempt
to control these differences. However, our study is limited by the patient-level covariates reported in each of the
studies, which were not consistent across trials. Therefore, it should be underlined that these summary results are
able to only describe the heterogeneity between studies but not the heterogeneity between patients, considering
that they reflect group averages rather than true individual data for potential moderators.
Moreover, we did not control for other potentially important confounders (i.e., microscopic vascular invasion,
histological grading and gene profiling) for which data are lacking and this could have affected our results [2].
However, we underline that despite the unavailability of individual data for covariates of each patient included in
the meta-analysis, we were still able to analyze progression and survival in a flexible mode. This approach most fits
survival trends, and return low values for frailty variance [41].
The available evidence from this meta-analysis of aggregate data enabling us to assess outcomes as time-dependent
events is sufficient to conclude that in patients with intermediate/advancedHCC treated with sorafenib: themedian
OS (10.0 months) and the median TTP (4.1 months) pooled actuarial probability are extremely variable, and no
single clinical or tumor characteristic can fully explain this heterogeneity; absence of MaVI and EHD, and HCV
etiology are associated with a higher likelihood of survival; HCC patients with etiology other than HCV should
early shift to second-line therapies; and presence of MaVI and EHD are predictors of tumor progression.
These pooled reported actuarial OS and TTP probabilities provide a useful benchmark for indirect comparisons
of the benefit of new first-line agents for the treatment of advanced HCC, and to better define the correct sequential
treatment with second-line agents after failure of sorafenib.
Future perspective
The identification of predictors of survival and progression in patients with HCC is crucial to switch from one
treatment to another, and this choice may occur several times throughout the history of patients with HCC. First, in
patients with intermediate HCC who received repeated locoregional treatments, it is not clear what is the best time
to shift from locoregional to systemic therapy. Subsequently, once the patient has been judged unfit to locoregional
treatment, physicians are faced with the choice to start sorafenib or lenvatinib as first-line systemic strategy. Finally,
patients with compensated cirrhosis who experienced HCC progression or adverse events to first-line therapy can
be shifted to a second-line treatment. To date, four drugs have been approved in the second-line setting: regorafenib
(in patients without adverse events to sorafenib), cabozantinib, ramucirumab (in patients with high alfa-fetoprotein
levels) and nivolumab (the first immunotherapy approved for HCC). All these drugs have been tested in patients
previously treated with sorafenib and there are no second-line RCTs conducted in patients previously treated with
lenvatinib. Unfortunately, which second line is the best and which patients will be able to tolerate several lines of
therapy remain to be clarified.
Nowadays, physicians could answer these questions in daily clinical practice by basing their decisions on the
inclusion criteria of the trials, and on expected toxicities. However, care should be taken in translating trial data
into real-world practice. In the future, identification of individual patient factors is needed to guide the choice
of the most appropriate treatment sequence and to select subgroups of patients who can obtain the most benefit
from immunotherapy. A meta-analysis of individual patient data could provide an accurate treatment comparison
in the setting of advanced HCC, in whom a significant heterogeneity is present; decision modeling could be
another methodological tool to rank different sequential strategies. Finally, the increase in the number of available
treatments makes urgently necessary to identify biomarkers and mechanisms of resistance that could guide the
choice of which therapy and when to shift into the sequence.
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Summary points
• Sorafenib is the recommended first-line systemic therapy for compensated patients with advanced hepatocellular
carcinoma (HCC) or intermediate HCC unfit for, or who failed locoregional therapies.
• Molecular predictors of response to sorafenib are lacking and the determination of the optimal point at which to
move from first to second-line therapy remains not clear.
• We performed a meta-analysis of reconstructed individual patients survival data from Kaplan–Meier curves of
Phase III randomized controlled trials assessing sorafenib as first-line therapy in intermediate/advanced HCC.
• We showed that the median overall survival (10.0 months) and the median time to radiological progression (4.1
months) pooled actuarial probability are extremely variable. No single clinical or tumor characteristic can fully
explain this heterogeneity.
• Absence of macrovascular invasion and extra-hepatic disease and HCV etiology are associated with a higher
likelihood of survival.
• HCC patients with etiology other than HCV should early shift to second-line therapies.
• Presence of macrovascular invasion and extra-hepatic disease are significant predictors of tumor progression.
• Our pooled actuarial overall survival and TTP probabilities provide a useful benchmark to indirectly compare the
benefit of new first-line agents for advanced HCC, and to better define the correct sequential treatment with
second-line agents after failure of sorafenib.
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